Company Filing History:
Years Active: 2024
Title: The Innovative Contributions of Steven S. Neben
Introduction
Steven S. Neben is a notable inventor based in Del Mar, California. He has made significant contributions to the field of biotechnology, particularly in the development of antiviral therapies. His work focuses on innovative methods to combat hepatitis C virus (HCV) infections.
Latest Patents
Steven S. Neben holds a patent for "Galnac conjugated modified oligonucleotides as miR-122 inhibitor having HCV antiviral activity with reduced hyperbilirubinemia side-effect." This patent describes compositions and methods for inhibiting miR-122 activity. The compositions feature specific nucleoside modifications that yield potent inhibitors of miR-122 activity and include moieties that facilitate delivery to the liver. These compositions may be administered to subjects infected with hepatitis C virus, providing a treatment option for HCV and related conditions.
Career Highlights
Steven is associated with Regulus Therapeutics Inc., a company dedicated to advancing RNA-targeted therapeutics. His work at Regulus Therapeutics has been instrumental in developing innovative solutions for viral infections. He has a strong focus on creating effective treatments that minimize side effects for patients.
Collaborations
Steven has collaborated with notable colleagues, including Charles R. Allerson and Timothy Wright. These collaborations have contributed to the advancement of research and development in the field of antiviral therapies.
Conclusion
Steven S. Neben's innovative work in the biotechnology sector, particularly in developing treatments for hepatitis C virus, showcases his commitment to improving patient outcomes. His contributions through patents and collaborations highlight the importance of innovation in addressing global health challenges.